<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Short QT syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Short QT syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Short QT syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles Antzelevitch, PhD, FACC, FAHA, FHRS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1561601136"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Short QT Syndrome (SQTS) is a rare inherited channelopathy (a disorder that affects the movement of ions through channels within the cell membrane) associated with marked shortened QT intervals and sudden cardiac death (SCD) in individuals with a structurally normal heart. In contrast to long QT syndrome, another channelopathy, ion channel defects associated with SQTS lead to abnormal abbreviation of repolarization, predisposing affected individuals to a risk of atrial and ventricular arrhythmias. </p><p>Since its first report in 2000, significant progress has been made in defining the genetic and cellular basis of SQTS as well as in therapeutic approaches to treating this syndrome. SQTS is a genetically heterogeneous disease associated with eight different genes encoding various cardiac ion channels, a carnitine transporter, and a chloride-bicarbonate anion exchanger. Data regarding genotype-phenotype correlation and genotype-specific treatment are promising but limited, primarily due to the lack of clinical cases.</p><p>The clinical presentation, diagnostic approach, and treatment modalities for SQTS will be discussed here. SCD and other channelopathies are discussed separately. (See  <a class="medical medical_review" href="/d/html/963.html" rel="external">"Overview of sudden cardiac arrest and sudden cardiac death"</a> and  <a class="medical medical_review" href="/d/html/1036.html" rel="external">"Congenital long QT syndrome: Epidemiology and clinical manifestations"</a>.)</p><p class="headingAnchor" id="H1561601143"><span class="h1">HISTORICAL BACKGROUND AND INITIAL REPORT</span><span class="headingEndMark"> — </span>In 1993, it was first proposed that shorter than normal QT intervals (&lt;400 milliseconds) are associated with a 2.4-fold increased risk for SCD [<a href="#rid1">1</a>]. An abnormally short QT interval observed before and after runs of VT/VF has been reported anecdotally [<a href="#rid2">2,3</a>]. Interestingly, certain species of kangaroo, known to have a high incidence of SCD, display an abnormally short QT interval as a normal feature on their electrocardiogram (ECG) [<a href="#rid4">4,5</a>].</p><p>SQTS was first described as a clinical entity in a report of four patients with extremely short QT intervals in association with paroxysmal atrial fibrillation and SCD [<a href="#rid6">6,7</a>]. In 2003, another study further described SQTS in two unrelated European families (six patients total) with a strong family history of sudden death in association with short QT interval on ECG [<a href="#rid8">8</a>]. Since then, over 200 cases of SQTS have been reported, and the existence of this novel channelopathy has been validated.</p><p class="headingAnchor" id="H1212774131"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Abbreviation of the QT interval, the time elapsed between ventricular depolarization and repolarization, on the surface ECG is caused by a decrease in the action potential duration (APD) of ventricular myocytes  (<a class="graphic graphic_figure graphicRef78354" href="/d/graphic/78354.html" rel="external">figure 1</a>). The upper limit of the normal QT interval is now fairly well defined, but the lower limit of the normal QT interval and the value below which it could be considered arrhythmogenic remain unclear [<a href="#rid9">9,10</a>]. The ECGs of the first few patients with SQTS showed extremely short QT and QTc intervals of less than 300 milliseconds. Since then, patients with SQTS with QT interval longer than 300 milliseconds have been reported; however, in most cases the QT and QTc interval have been less than 360 milliseconds. Yet the diagnosis of SQTS is complicated due to the overlapping QT range of affected individuals and apparently healthy individuals. </p><p>To define the lower limit of the QT interval, many experts refer to a comprehensive study that investigated the distribution of normal QT interval in 14,379 healthy individuals [<a href="#rid11">11</a>]. The study established the formula (Rautaharju's formula) by which the QT interval can be predicted as:</p><p>QT predicted (QTp) = 656/(1+ heart rate/100)</p><p>The prevalence of QT interval shorter than 88 percent of QTp (QT/QTp &lt;88 percent, which is equivalent to two standard deviations below the mean) was 0.03 percent. Based on this observation, it was suggested that QT intervals less than 88 percent of QTp (two standard deviations below mean predicted value) at a particular heart rate may be considered as short QT intervals. For example, at a heart rate of 60 beats per minute (bpm), per Rautaharju's formula, QTp would be 410 milliseconds. Eighty-eight percent of QTp (410 milliseconds) would be 360 milliseconds. QT interval values less than 80 percent of QTp may be considered extremely short (which is equivalent to 330 milliseconds at a heart rate of 60 beats per minute) [<a href="#rid12">12-15</a>]. </p><p>Clinical experience clearly indicates that the vast majority of patients with QTc values in the 330 to 360 range are not at risk, although a select few may be. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H5697920"><span class="h1">PREVALENCE OF A SHORT QT INTERVAL</span><span class="headingEndMark"> — </span>In contrast to the epidemiologic data available for many other ECG parameters, including long QT intervals, the precise prevalence of a short QT interval in the general population is unknown but appears to be 2 percent or less when using a cutoff of 360 milliseconds. This is largely the case due to the long-standing failure to identify any risk associated with shorter-than-normal QT intervals as well as the varying definitions of what constitutes a shorter-than-normal QT interval.</p><p>Several large cohorts have attempted to identify the frequency of short QT interval in the general population [<a href="#rid16">16-19</a>]. The precise definition of a short QT has varied slightly in each of the cohorts, but in all of the studies, patients classified as having a short QT interval had a rate-corrected QTc of 369 milliseconds or less. The prevalence was estimated as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In a Finnish cohort of 10,822 middle-aged (mean 44 years) patients, 0.4 percent had a short QTc interval (&lt;340 milliseconds), and 0.1 percent had a very short QTc interval (&lt;320 milliseconds) [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Swiss cohort of 41,767 army conscripts (99.6 percent male, mean age 19 years), 1 percent had a short QTc interval (&lt;347 milliseconds), and 0.02 percent had a very short QTc interval (&lt;320 milliseconds) [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an American cohort of 46,129 healthy volunteers (53 percent female), 2 percent had a QTc interval ≤360 milliseconds [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Japanese cohort of 114,334 patients with ECGs stored in an electronic database, 0.37 percent were found to have short QTc intervals (≤357 milliseconds in males, ≤364 milliseconds in females) [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H1561601157"><span class="h1">GENETIC BASIS</span><span class="headingEndMark"> — </span>SQTS is a genetically heterogeneous disease with mutations in eight different genes (three gain of function and five loss of function) that encode different cardiac ion channels, a carnitine transporter, and a chloride-bicarbonate anion exchanger (AE3), having been identified and termed SQT1 to SQT8 based on the chronology of their discovery  (<a class="graphic graphic_table graphicRef72304" href="/d/graphic/72304.html" rel="external">table 1</a>). SQT1 and SQT3-8 have been reported in a familial setting, and SQT2 is reported only in a single patient in a sporadic setting. SQTS traits are transmitted in an autosomal dominant fashion. Many of the genes involved in SQTS are the same as those responsible for LQTS; however, the net effect of the pathogenic variants in SQTS is to increase repolarizing forces, an effect opposite to that encountered in LQTS. (See  <a class="medical medical_review" href="/d/html/1009.html" rel="external">"Congenital long QT syndrome: Pathophysiology and genetics", section on 'Types of congenital LQTS'</a>.) </p><p>The largest available case series of SQTS describes the clinical presentation of 29 patients with SQTS [<a href="#rid20">20</a>]. The most common form of SQTS (SQT1) was linked to pathogenic variants in KCNH2, the gene encoding the α-subunit of the rapid delayed rectifier K<sup>+</sup> channel (I<sub>Kr</sub>)  (<a class="graphic graphic_figure graphicRef70771" href="/d/graphic/70771.html" rel="external">figure 2</a>). Approximately 25 percent of patients had a mutation in <em>KCNH2</em>, and no pathogenic variant was found in the rest of the patients. Mutations in <em>KCNQ1</em> and <em>KCNJ2</em> were not detected, and <em>CACNA1c,</em> <em>CACNB2b, and CACNA2D1</em> were not screened. A genetic cause remains to be identified in the majority of SQTS cases [<a href="#rid21">21</a>].</p><p>The N588K pathogenic variant in <em>KCNH2</em> was first identified in three separate families with shorter than normal QT intervals and a high incidence of ventricular arrhythmias and sudden death [<a href="#rid8">8,22</a>]. Patch clamp analysis of N588K revealed this mutation completely removed inactivation over a physiological range of potentials, resulting in a dramatic increase in I<sub>Kr</sub> [<a href="#rid23">23,24</a>]. A second mutation at T618I in <em>KCNH2</em> has been discovered and linked to SQT1 [<a href="#rid25">25</a>]. The T618I-<em>KCNH2</em> missense mutation was recently designated as a hotspot, having been identified in 18 members of seven unrelated families [<a href="#rid26">26</a>]. </p><p>Many patients with SQTS carrying pathogenic variants in the L-type calcium channel genes (<em>CACNA1C, CACNB2</em> and <em>CACNA2D1</em>) manifest an ST segment elevation on the surface ECG in addition to a shorter than normal QT interval and have a combined Brugada/Short QT syndrome [<a href="#rid27">27,28</a>]. Most patients harboring a calcium channel mutation who display normal QT intervals have been shown to carry secondary genetic variations that are known to prolong the QT interval. QT-prolonging variations (p.D601E-<em>CACNB2b, </em>p.K897T-<em>KNCH2, </em>p.T10M-<em>KCNE2, </em>p.R1047L<em>-KCNH2, </em>p.D76N<em>-KCNE1, </em>p.G643S<em>-KCNQ1) </em>were found in 12 of the 14 BrS probands presenting with a normal QTc [<a href="#rid29">29</a>]. </p><p>Initially, only pathogenic variants in genes encoding the cardiac potassium and calcium channels were implicated in SQTS. However, a subsequent report provides evidence that a disturbance of long-chain fatty acid metabolism can influence the morphology and the electrical function of the heart, leading to development of SQTS [<a href="#rid30">30</a>]. In this case series, three patients affected by primary systemic carnitine deficiency presented with SQTS associated with ventricular fibrillation. Primary carnitine deficiency is a rare (1:50,000) autosomal recessive disorder caused by defective transport of carnitine into the cell, in which mutations in SLC22A5 have been implicated [<a href="#rid31">31,32</a>]. Administration of oral DL-carnitine or <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">L-carnitine supplements</a> (5 g/day) over a period of months abolished the ECG and arrhythmic manifestations of the syndrome. Additional evidence in support of the relationship between carnitine deficiency and SQTS was obtained by using a mouse model of carnitine deficiency induced by long-term subcutaneous perfusion of MET88 [<a href="#rid30">30</a>]. Previous studies have reported that the absence of long-chain fatty acids leads to an increase in the rapidly activating delayed rectifier potassium channel current (I<sub>Kr</sub>) [<a href="#rid33">33</a>], which may participate in the abbreviation of the QT interval in primary carnitine deficiency. This study suggests that long-chain fatty acids can directly regulate I<sub>Kr</sub>. The effects of Class III antiarrhythmic agents have not been tested either in humans with primary carnitine deficiency or in the mouse model of the syndrome. (See  <a class="medical medical_review" href="/d/html/115918.html" rel="external">"Specific fatty acid oxidation disorders", section on 'Carnitine transporter deficiency'</a>.) </p><p>Another study has implicated loss-of-function mutations in the chloride bicarbonate anion exchanger (AE3) encoded by <em>SLC4A3</em> gene in two unrelated three and four-generation families with SQTS [<a href="#rid26">26</a>]. The <em>SLC4A3</em> c.1109 G &gt;A, p.R370H variant caused reduced surface expression of the anion exchanger and reduced membrane bicarbonate transport. Additional evidence in support of this as a cause of SQTS derives from the demonstration that <em>SLC4A3</em> knockdown in zebrafish causes increased cardiac pHi, short QTc, and reduced systolic duration, which is rescued by wildtype <em>SLC4A3</em>. Furthermore, experimental data suggested that an increase in pHi and decrease in [Cl<sup>−</sup>]i abbreviate the action potential duration [<a href="#rid26">26</a>]. Cascade screening in the two families identified a total of 23 carriers of the <em>SLC4A3</em> variant. Mutation carriers displayed a mean QTc of 340±18 ms compared to a mean QTc of 402±24 ms in the 19 non-carrier family members.</p><p>In a 2019 study of variants previously catalogued as pathogenic in SQTS according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, only 9 of the 32 variants studied (28 percent) were shown to have a conclusive pathogenic role [<a href="#rid34">34</a>]. All nine definitively pathogenic variants were located in the genes encoding for the three potassium channel genes <em>KCNQ1, KCNH2, or KCNJ2</em>. Variants in genes encoding calcium or sodium channels were associated with electrical alterations concomitant with shortened QT intervals but not necessarily SQTS.</p><p>In 2021, a study with a similar evidence-based reappraisal of previously reported genes found that only one gene studied (<em>KCNH2</em>) was definitively linked to short QT pathogenesis [<a href="#rid35">35</a>]. Three other pathogenic variants (<em>KCNQ1</em>, <em>KCNJ2</em>, <em>SLC4A3</em>) had strong to moderate evidence of being causative of SQTS. It is noteworthy that the majority of genetic evidence was derived from very few variants (five in <em>KCNJ2</em>, two in <em>KCNH2</em>, one in <em>KCNQ1/SLC4A3</em>).</p><p class="headingAnchor" id="H175416"><span class="h1">CELLULAR BASIS OF ARRHYTHMOGENESIS</span><span class="headingEndMark"> — </span>The QT interval is determined by the ventricular action potential duration, which in turn is dependent upon a delicate balance of currents active during the repolarization phase of the action potential  (<a class="graphic graphic_figure graphicRef78354" href="/d/graphic/78354.html" rel="external">figure 1</a>). An increase in net outward current due to either a reduction in inward depolarizing currents like I<sub>Ca</sub> (SQT4- SQT6) or augmentation of outward repolarizing currents such as I<sub>Kr </sub>(SQT1), I<sub>Ks</sub> (SQT2), I<sub>K1</sub> (SQT3), or a combination thereof, can shift the balance of current favoring early repolarization, thus leading to abbreviation of action potential duration, refractoriness, and QT interval  (<a class="graphic graphic_figure graphicRef70771" href="/d/graphic/70771.html" rel="external">figure 2</a>).</p><p>Available data suggest that abbreviation of the action potential in SQTS is heterogeneous with preferential abbreviation of either epicardial or endocardial cells as compared with subendocardial M cells, resulting in tall, positive T waves on the ECG and an increase in transmural dispersion of repolarization (TDR) [<a href="#rid36">36,37</a>]. Dispersion of repolarization serves as substrate, and abbreviation of wavelength (product of refractory period and conduction velocity) promotes the initiation and maintenance of reentry under conditions of SQTS. </p><p>The trigger responsible for generating the premature beat that precipitates polymorphic ventricular tachycardia (VT) in SQTS is not known but may involve a phase 2 reentry or late phase 3 early afterdepolarization mechanism, which may give rise to R-on-T extrasystoles [<a href="#rid37">37,38</a>]. Alternatively, re-excitation of the ventricles from the Purkinje fiber network may initiate the arrhythmia [<a href="#rid23">23,39</a>].</p><p>In the experimental setting, shortening of the action potential duration (and thus QT interval) results in a reduction in contractility [<a href="#rid40">40,41</a>]. However, reports have shown that while electrical repolarization in SQTS patient is abbreviated, mechanical contraction is not, suggesting an electromechanical dissociation [<a href="#rid42">42</a>]. </p><p>A gain-of-function mutation augments outward potassium current in SQT1-3, and a loss-of-function mutation reduces I<sub>Ca </sub>in SQT4-6 [<a href="#rid22">22,27,28,43,44</a>]. Carnitine deficiency is thought to increase I<sub>Kr</sub> in LQT7 and a combination of an increase in pH and reduction in intracellular Cl<sup>-</sup> contributes to action potential duration abbreviation in LQT8. T<sub>peak</sub>-T<sub>end</sub>/QT ratio, an ECG index of spatial dispersion of repolarization, is significantly augmented in most cases of SQTS, suggesting an increase in TDR at the cellular level [<a href="#rid26">26,45,46</a>]. Interestingly, this ratio is amplified in patients who are symptomatic [<a href="#rid47">47</a>]. The increase in TDR is known to predispose to phase 2 reentry and may be responsible for the closely-coupled premature ventricular extrasystole that precedes the onset of polymorphic VT in patients with SQTS [<a href="#rid48">48,49</a>].</p><p>The preclinical models discussed above and others, including <strong>t</strong>ransgenic rabbits generated by oocyte-microinjection of beta-myosin-heavy-chain-promoter-KCNH2/HERG-N588K constructs, offer opportunities to improve the diagnosis and treatment of patients with SQTS. They have proven useful in identification of genotype–phenotype associations and have uncovered disease mechanisms and revealed underlying pathophysiology of SQTS. These discoveries have been leveraged in drug development for treatment of patients with SQTS [<a href="#rid21">21,50,51</a>]. </p><p class="headingAnchor" id="H1561601164"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of SQTS is variable, and many patients are asymptomatic [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H4204566773"><span class="h2">Typical presentation</span><span class="headingEndMark"> — </span>The initial presentation and subsequent clinical course of SQTS varies among different families and even within different members of the same family, as shown in the following case series of 29 patients [<a href="#rid20">20</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>The first manifestation of the disease was reported at an age as young as one month or as old as 80 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sixty-two percent of the patients (18 out of 29) were symptomatic. The most frequently reported symptoms were:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac arrest – 34 percent (this was the initial symptom in 28 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Palpitations – 31 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Syncope – 24 percent </p><p class="bulletIndent2"><span class="glyph">•</span>Atrial fibrillation – 17 percent </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>38 percent of the patients (11 out of 29) were asymptomatic and were diagnosed based on a strong family history of arrhythmic symptoms including SCD, a common finding in familial forms of SQTS. </p><p></p><p>The circumstances surrounding the onset of symptoms are highly variable, and episodes of sudden cardiac death (SCD) have been reported at rest, following a loud noise, during exercise, and during routine daily activities. SCD occurred in the first month of life in two patients, suggesting that SQTS may contribute to sudden infant death syndrome (SIDS) [<a href="#rid20">20</a>]. </p><p>Arrhythmogenic events have been reported at all ages from infants to octogenarians, but the first year of life appears to be the most worrisome, with a 4 percent rate of cardiac arrest [<a href="#rid52">52</a>]. One-third of cases present with SCD as their first event, and up to 80 percent show a personal or family history of SCD [<a href="#rid53">53</a>]. Lethal events occur in both sexes, but a slight male predominance appears to exist which may be due to testosterone modulation of potassium currents as seen in other channelopathies [<a href="#rid54">54-56</a>]. Male patients with SQTS presented more often with syncope as compared with female patients (24 percent versus 7 percent) and other presenting symptoms such as palpitations as well as SCD were not significantly different between the sexes [<a href="#rid55">55</a>]. </p><p>The following findings were noted in a report of 53 patients from the European Short QT Registry (75 percent males; median age 26 years) who were followed for up to 64±27 months [<a href="#rid57">57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A familial or personal history of cardiac arrest was present in 89 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Sudden death was the clinical presentation in 32 percent</p><p class="bulletIndent1"><span class="glyph">●</span>The average QTc was 314±23 milliseconds</p><p></p><p>Symptomatic patients were found to have a high risk of recurrent arrhythmic events, with a high risk of sudden death in all age groups [<a href="#rid57">57</a>].</p><p>In a Japanese cohort of 65 mutation-positive patients, SQT1 patients first presented at an older age (SQT1: 35±19years; SQT2: 17±25years; SQT3-6: 19±15years). SQT2 exhibited a higher prevalence of bradyarrhythmia (SQT2: 6/8, 75 percent; non-SQT2: 5/57, 9 percent) and atrial fibrillation (SQT2: 5/8, 63 percent; non-SQT2: 12/57, 21 percent) [<a href="#rid58">58</a>].</p><p>Echocardiographic insights point to mechanical correlates, suggesting that systolic function may be affected as well, as shown in a study of 15 SQTS patients which identified a significant dispersion of myocardial contraction [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H1561601171"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>As with any survivor of sudden cardiac death (SCD), a history and physical examination focusing on potential underlying etiologies of SCD (eg, myocardial ischemia, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, intoxications) should be performed, along with a routine surface ECG. Paroxysmal atrial fibrillation is very common in patients with SQTS; thus, diagnosis of SQTS should be considered in young individuals with lone atrial fibrillation with shorter than normal QT intervals. A history of arrhythmic symptoms, family history of lone atrial fibrillation, or primary or resuscitated ventricular fibrillation (VF) or SCD may provide additional clues. The isolated presence of short QT interval without associated arrhythmogenic complication warrants further interrogation to rule out SQTS.</p><p>Our approach to additional testing, which may include exercise stress testing, invasive electrophysiology studies, echocardiography, 24-hour ambulatory monitoring, and cardiac magnetic resonance imaging, is discussed separately. (See  <a class="medical medical_review" href="/d/html/970.html" rel="external">"Cardiac evaluation of the survivor of sudden cardiac arrest"</a>.)</p><p class="headingAnchor" id="H341508"><span class="h2">Electrocardiographic findings</span><span class="headingEndMark"> — </span>Typical ECG findings associated with SQTS include the following  (<a class="graphic graphic_waveform graphicRef51616" href="/d/graphic/51616.html" rel="external">waveform 1</a>) [<a href="#rid6">6,8,20,60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormally short QT interval, usually &lt;360 milliseconds with a range of 220 to 360 milliseconds</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of ST segment</p><p class="bulletIndent1"><span class="glyph">●</span>Tall and peaked T waves in the precordial leads, which can be positive or negative, symmetrical or asymmetrical</p><p class="bulletIndent1"><span class="glyph">●</span>Poor rate adaptation of QT interval (diminished rate dependence) [<a href="#rid61">61</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged T<sub>peak</sub>-T<sub>end </sub>interval and T<sub>peak</sub>-T<sub>end</sub>/QT ratio [<a href="#rid45">45,46</a>]</p><p></p><p>The reduced rate adaptation of the QT interval makes SQTS difficult to diagnose at fast heart rates. Calculation of QTc using Bazett’s correction is invalid and when applied erroneously brings QTc into the normal range. Because of the impaired QT adaptation to heart rate changes in patients with SQTS, we recommend measurement of the QT interval at a heart rate between 50 and 70 beats per minute. ECG patterns that support the diagnosis include PQ segment deviation, tall and symmetrical T waves with a very short or negligible ST segment, early repolarization pattern, and impaired adaptation of the QT interval during exercise [<a href="#rid16">16,42,61-63</a>].</p><p>Most patients with SQTS have QTc &lt;340 milliseconds with a range of 210 to 320 milliseconds. However, in patients with SQT4, SQT5, and SQT8, QTc intervals are slightly longer (340 to 360 milliseconds).</p><p>Depression of the PQ segment, rarely seen in the ECG of apparently healthy individuals but which is seen in patients with acute pericarditis and inferior myocardial infarction, has been reported in patients with SQTS. Among a cohort of 64 patients with SQTS (75 percent male, mean QTc 321 milliseconds) who were compared with 117 healthy controls with normal QT intervals, PQ depression was seen in at least one lead in 81 percent of patients (compared with 24 percent of controls) [<a href="#rid62">62</a>]. PQ depression was most commonly seen in leads II, V3, aVF, V4, and I (67, 47, 42, 39, and 39 percent of patients with SQTS, respectively). The presence of PQ depression in asymptomatic patients or those with syncope or an arrhythmia should prompt close scrutiny of the QT interval for the possibility of a short QT interval. PQ dispersion in this setting is thought to reflect spatial dispersion of repolarization within the atria.</p><p>In cases of SQT4, 5, and 6, short QT intervals may appear together with a Brugada type ST segment elevation in the right precordial leads V1-V3 at baseline or after administration of a potent sodium channel blocker  (<a class="graphic graphic_waveform graphicRef51616" href="/d/graphic/51616.html" rel="external">waveform 1</a>) or other unmasking agent, such as a potassium channel opener (I<sub>KATP</sub> activator) [<a href="#rid28">28</a>]. Approximately 65 percent of patients with SQTS have ECG features of early repolarization, characterized by J-point elevation in the inferolateral leads, which may also be associated with an increased likelihood of increased arrhythmic events [<a href="#rid63">63,64</a>]. (See  <a class="medical medical_review" href="/d/html/1020.html" rel="external">"Brugada syndrome: Epidemiology and pathogenesis", section on 'Brugada pattern versus Brugada syndrome'</a>.)</p><p>When the diagnosis of SQTS is suspected, a resting 12-lead ECG should be performed at a heart rate within normal limits, preferably 50 to 70 beats per minute. In patients with SQTS, the QT interval fails to lengthen appropriately with a decrease in the heart rate [<a href="#rid61">61</a>]. As a consequence, QT correction using Bazett's or comparable formulas (<a class="calc calc_professional" href="/d/html/13459.html" rel="external">calculator 1</a>) will overcorrect at initially fast rates, leading to a false negative diagnosis. Overnight Holter monitoring or long-term ECG monitoring may prove helpful in such cases as this allows for analysis of the QT interval during periods of slower heart rate (ie, sleep) and also allows for patient-specific QT correction for heart rate. (See  <a class="medical medical_review" href="/d/html/2115.html" rel="external">"ECG tutorial: Basic principles of ECG analysis", section on 'QT interval'</a>.)</p><p>While data are relatively sparse, owing to the rarity of the syndrome, the picture that appears to be developing is that SQT1 and 2 probands generally manifest symmetrical tall peaked T waves, whereas SQT3 probands display asymmetrical tall peaked T waves with a more rapidly descending than ascending limb of the T wave [<a href="#rid44">44</a>]. SQT4, 5, 6, 7, and 8 show variable T wave heights but are usually symmetrical. In most cases, a distinct ST segment is short or absent, with the T wave originating from the S wave.</p><p class="headingAnchor" id="H1561601193"><span class="h2">Electrophysiological study</span><span class="headingEndMark"> — </span>Although electrophysiological study (EPS) has a role in confirming the diagnosis by revealing short ventricular refractory periods, its role in risk stratification remains unclear. As such, EPS is not routinely performed unless the diagnosis of SQTS remains unclear based on the available ECG data. (See  <a class="medical medical_review" href="/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a>.)</p><p>During invasive EPS, patients with SQTS characteristically show extremely short atrial and ventricular effective refractory periods (ERP), regardless of genotype [<a href="#rid8">8,20,28,43,44</a>]. The ventricular ERP measured at the right ventricular apex varies between 140 and 180 milliseconds at a cycle length of 500 to 600 milliseconds and 130 to 180 milliseconds at pacing cycle length of 400 to 430 milliseconds. Atrial ERP measured in the high lateral right atrium varies between 120 and 180 milliseconds at a cycle length of 600 milliseconds. The programmed electrical stimulation with two to three premature stimuli down to refractoriness induced both atrial fibrillation and VF in many patients. The inducibility of VF at EPS in SQTS patients is approximately 60 percent. Moreover, in one case series, VF was inducible at EPS in only three of six patients with clinically documented VF, suggesting that the sensitivity of EPS for the inducibility of VF is low [<a href="#rid20">20</a>]. </p><p class="headingAnchor" id="H175129"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>In patients where SQTS is suspected as the diagnosis, based on ECG findings and clinical history, genetic testing of the patient should be considered. Given the relative scarcity of this clinical entity, decisions regarding genotyping should be performed in collaboration with an electrophysiologist or other clinician with expertise in the evaluation and diagnosis of patients with suspected SQTS. (See <a class="local">'Genetic basis'</a> above and <a class="local">'Diagnosis and diagnostic criteria'</a> below.)</p><p class="headingAnchor" id="H3633016551"><span class="h2">Screening family members</span><span class="headingEndMark"> — </span>First-degree relatives of those diagnosed with SQTS should undergo clinical screening with an ECG and genetic testing. Mutation-specific genetic testing is recommended<strong> </strong>for all family members and relatives suspected of SQTS following the identification of the SQTS-causative mutation in an index case [<a href="#rid65">65</a>]. Family members who test positive for the familial mutation should consult a cardiologist with expertise in SQTS to discuss further management. Conversely, a negative genetic test for the familial mutation obviates the need for repeated follow-up.</p><p class="headingAnchor" id="H2323074656"><span class="h1">DIAGNOSIS AND DIAGNOSTIC CRITERIA</span><span class="headingEndMark"> — </span>While ECG findings in SQTS can be suggestive of the diagnosis, the solitary presence of a shorter than normal QT interval is not always diagnostic. Clinical history, family history of sudden death, and genotype results can all contribute to the diagnostic certainty. While there is ongoing debate on the optimal diagnostic strategy for SQTS, the authors and editors of this topic agree with and recommend following the proposed diagnostic criteria for SQTS.</p><p>The 2013 HRS/EHRA/APHRS Expert Consensus Statement and the 2015 ESC Guidelines indicate that a QTc of 330 or 340 milliseconds alone may be diagnostic of SQTS, but that SQTS should be considered in the presence of a QTc of &lt;360 milliseconds when accompanied by a confirmed pathogenic mutation, family history of SQTS, family history of sudden death at age &lt;40 years, or survival from a VT/VF episode in the absence of heart disease [<a href="#rid66">66,67</a>].</p><p>Based on a comprehensive review of 61 reported cases of SQTS, proposed diagnostic criteria were developed to facilitate the evaluation of individuals suspected to have SQTS [<a href="#rid10">10</a>]. A scoring system was developed based on ECG characteristics, clinical presentation, family history, and genetic findings  (<a class="graphic graphic_table graphicRef65743" href="/d/graphic/65743.html" rel="external">table 2</a>). The most controversial aspect of the differential diagnosis of SQTS involves the QT interval cutoff, as shown by the increasing number of points assigned to shorter QT intervals in the proposed diagnostic criteria.</p><p class="headingAnchor" id="H341687"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Before arriving at a diagnosis of SQTS, other potential causes for QT shortening should be excluded.</p><p class="headingAnchor" id="H616552"><span class="h2">Normal variant</span><span class="headingEndMark"> — </span>The sole presence of a shorter-than-normal QT interval does not appear to be diagnostic for SQTS and, in fact, may represent a normal variant in many people. Up to 2 percent of the population has QT intervals ≤360 milliseconds, highlighting the importance of utilizing the diagnostic criteria for the diagnosis of SQTS. (See <a class="local">'Prevalence of a short QT interval'</a> above and <a class="local">'Diagnosis and diagnostic criteria'</a> above.) </p><p class="headingAnchor" id="H175259"><span class="h2">Acquired causes of short QT interval</span><span class="headingEndMark"> — </span>Secondary causes of short QT interval are reviewed in  (<a class="graphic graphic_table graphicRef59159" href="/d/graphic/59159.html" rel="external">table 3</a>). Briefly, these include: </p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic and electrolyte abnormalities such as hyperkalemia, acidosis, and hypercalcemia. </p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthermia.</p><p class="bulletIndent1"><span class="glyph">●</span>Drug effects from digitalis, acetylcholine, or catecholamines. </p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial ischemia.</p><p class="bulletIndent1"><span class="glyph">●</span>Vagal tone. </p><p class="bulletIndent1"><span class="glyph">●</span>Combination of genetic and secondary causes, including hyperkalemia, hypercalcemia, acidosis, myocardial ischemia, and increased vagal tone (QTc prolongation is similar in having potential genetic and secondary causes).</p><p></p><p class="headingAnchor" id="H175234"><span class="h2">Deceleration-dependent shortening of the QT interval</span><span class="headingEndMark"> — </span>A rare but interesting paradoxical ECG phenomenon called deceleration-dependent shortening of QT interval (DDSQTI) should also be considered in the differential diagnosis of SQTS [<a href="#rid6">6</a>]. Strong parasympathetic stimulation can lead to bradycardia and concurrent activation of myocardial acetylcholine-sensitive K<sup>+</sup> channels (K<sub>ACh</sub>). In such cases, the QT interval abbreviates paradoxically with a decrease in heart rate instead of lengthening. Such shortening of the QT interval may be transient and should resolve as parasympathetic tone decreases. </p><p class="headingAnchor" id="H1561601207"><span class="h1">MANAGEMENT OF PATIENTS WITH A SHORT QT INTERVAL</span><span class="headingEndMark"> — </span>As discussed previously, the sole presence of a shorter-than-normal QT interval on an ECG does not appear to be diagnostic for the short QT syndrome and, in isolation, may not be associated with an increased risk of sudden cardiac death (SCD). Because the rate of serious complications of implantable cardioverter-defibrillator (ICD) therapy is not trivial, particularly over the life of a young patient, it is important to discriminate between patients with an isolated short QT interval and those who meet the criteria for SQTS  (<a class="graphic graphic_table graphicRef65743" href="/d/graphic/65743.html" rel="external">table 2</a>). Prior to making a final decision regarding the management of these patients, acquired causes of a shortened QT interval should be excluded. (See <a class="local">'Acquired causes of short QT interval'</a> above.)</p><p class="headingAnchor" id="H3288843"><span class="h2">Patients with low/intermediate probability of SQTS</span><span class="headingEndMark"> — </span>There are no randomized trials and few observational studies of patients assessing the prognosis of patients with isolated short QT intervals who have no apparent clinical history, family history, or genetic criteria suggestive of SQTS [<a href="#rid68">68</a>]. As such, the following management strategies for such patients are based on expert opinion [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a short QT interval (330 to 360 milliseconds) who have none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS are classified as low probability for the diagnosis of SQTS. </p><p></p><p class="bulletIndent1">For these low-probability patients, we suggest no specific pharmacologic or device-based therapy. This approach is consistent with the published recommendations in the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of SCD [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a markedly shortened QT interval (&lt;330 milliseconds) are classified as intermediate-probability for the diagnosis of SQTS despite having none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS. </p><p></p><p class="bulletIndent1">For these intermediate-probability patients, there are limited data available to guide management. However, we suggest no specific pharmacologic or device-based therapy. We do suggest referral to an electrophysiologist for comprehensive testing, including genetic screening, if this has not yet been completed. </p><p></p><p class="headingAnchor" id="H3288858"><span class="h2">Patients with a high probability of SQTS</span><span class="headingEndMark"> — </span>Most patients with a QT interval &lt;350 milliseconds and at least one criterion from the list of clinical history, family history, or genotype criteria will be classified as high-probability for the SQTS. Because of the association between SQTS and sudden cardiac death due to arrhythmias, therapy with an ICD is recommended in these patients, along with consideration of antiarrhythmic therapy if appropriate shocks are frequent.</p><p class="headingAnchor" id="H1561601214"><span class="h3">Implantable cardioverter-defibrillator</span><span class="headingEndMark"> — </span>Patients with SQTS are at a very high risk for SCD [<a href="#rid15">15</a>]. As such, we recommend ICD implantation for both primary and secondary prevention of SCD in patients with SQTS unless absolutely contraindicated or refused by the patient. Because the sensitivity of inducibility of ventricular fibrillation (VF) is only 50 percent, failure to induce VF during EP study does not preclude future risk of SCD [<a href="#rid20">20,49</a>]. Accordingly, a negative EP study should not defer a clinician's decision to implant an ICD. Professional society guidelines recommend ICD implantation as a class I indication in symptomatic patients with a diagnosis of SQTS who are survivors of a cardiac arrest and/or have documented spontaneous sustained ventricular tachycardia with or without syncope [<a href="#rid67">67,69</a>]. ICD implantation may be considered (class IIb) in asymptomatic patients with a diagnosis of SQTS and a family history of SCD [<a href="#rid67">67</a>].</p><p>Oversensing of the T wave is a frequent clinical problem encountered in patients with SQTS who receive an ICD [<a href="#rid70">70</a>]. The tall, peaked, and closely coupled T waves are often mistakenly sensed as R waves, leading to inappropriate ICD shocks. Reprogramming the decay delay, the sensitivity, or both generally prevents such inappropriate discharges. Caution must be exercised to avoid programming modifications that prevent the detection of lethal ventricular tachyarrhythmia. (See  <a class="medical medical_review" href="/d/html/989.html" rel="external">"Cardiac implantable electronic devices: Long-term complications"</a>.)</p><p class="headingAnchor" id="H3297247769"><span class="h3">Ablation therapy</span><span class="headingEndMark"> — </span>There is limited evidence regarding the use of ablation therapy in SQTS. In a single case report, radiofrequency ablation of PVCs appeared to be successful in controlling ventricular arrhythmic events [<a href="#rid71">71</a>]. Further studies are needed.<sup> </sup></p><p class="headingAnchor" id="H1561601230"><span class="h3">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Pharmacologic therapy is primarily used as an adjunct to ICD placement, with a goal of reducing the likelihood of additional ICD shocks. However, pharmacologic therapy may be the primary treatment modality in patients who refuse ICD placement, patients with an absolute contraindication to ICD placement, or in very young patients in whom ICD implantation is problematic. For patients with SQTS who have refused or are not candidates for ICD therapy, or in those with recurrent ventricular arrhythmias resulting in frequent ICD therapy, we recommend adjunctive pharmacologic therapy with QT-prolonging drugs. In the case of SQT1, we recommend <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> rather than a class IC or class III  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 4</a>) antiarrhythmic drug [<a href="#rid69">69</a>]. In other forms of SQTS, data are too limited to permit specific suggestions or recommendations. </p><p>Data regarding pharmacologic therapy in SQTS are very limited, with much of the data pertaining to patients with SQT1:</p><p class="bulletIndent1"><span class="glyph">●</span>Four different antiarrhythmic drugs, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="8548" href="/d/drug information/8548.html" rel="external">ibutilide</a>, and hydroquinidine, were tested in six patients with SQT1 to determine their effects on various electrophysiologic properties [<a href="#rid72">72</a>]. Only hydroquinidine, a class IA antiarrhythmic drug  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 4</a>), normalized the QT interval, increased ventricular ERP, and rendered VF noninducible. In a one-year follow-up, patients treated with hydroquinidine remained asymptomatic, and no further episodes of ventricular arrhythmia were detected [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term treatment with hydroquinidine (hydroquinidine 584±53 mg/day) was evaluated in a cohort of 17 patients with SQTS (82 percent male, mean age 29 years, mean QTc pretreatment 331 milliseconds [QTc &lt;320 milliseconds in four patients], previous aborted SCD in six patients), among whom 15 patients continued treatment for an average of six years (two discontinued treatment due to gastrointestinal intolerance) [<a href="#rid73">73</a>]. The QTc increased by an average of 60 milliseconds with treatment, and no life-threatening ventricular arrhythmias were seen during the six years of treatment. The annual rate of life-threatening arrhythmic events in patients with a previous cardiac arrest dropped from 12 to 0 percent on hydroquinidine therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a> has proved to be effective in prolonging the QT interval and restoring the ventricular effective refractory period towards normal [<a href="#rid74">74</a>]. The combination of disopyramide and nifekalant, a class III agent available primarily in Japan, was reported in one patient to increase QTc to &gt;410 milliseconds [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> has been shown to prolong the QT interval in two patients with SQTS of unknown genotype [<a href="#rid48">48</a>].</p><p></p><p>The failure of class IC and pure class III antiarrhythmic drugs in SQT1 caused by the N588K mutation in KCNH2 is due to the fact that this mutation by removing inactivation of the I<sub>Kr</sub> channel results in a desensitization of the channel to these agents. Class III agents such as <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>, E-4031, and <a class="drug drug_general" data-topicid="8904" href="/d/drug information/8904.html" rel="external">dofetilide</a> have a greater affinity for the inactivated state of the channel. <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">Quinidine</a>, by virtue of its effect to block the activated state of the I<sub>Kr</sub> channel, was reasoned to be more effective in this setting in which the inactivated state of the channel is lost.</p><p>It is thought that the efficacy of <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> in SQT1 is due to its ability to inhibit the N588K channel at pharmacologically relevant concentrations, presumably due not only to its ability to block the activated state of the I<sub>Kr</sub> channel, but also its ability to block other outward currents, particularly I<sub>Ks. </sub>Quinidine's multi-ion channel inhibition may underlie its effectiveness in other forms of SQTS, particularly SQT4-SQT6 where its I<sub>to</sub> blocking action may provide a therapeutic edge over other antiarrhythmic drugs by reducing the substrate and trigger for Brugada syndrome. Prolongation of the QT interval by quinidine has been reported in one patient with SQT4 [<a href="#rid28">28</a>]. </p><p>One study has identified another missense mutation in hERG (T618I), which produces a more modest increase in I<sub>Kr</sub> than reported for the N588K-hERG variant. Interestingly, all drugs studied, including <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> and D-sotalol, retained their ability to inhibit the I<sub>Kr</sub> current recorded with this genetic variant [<a href="#rid76">76</a>].</p><p>The 2013 HRS/EHRA/APHRS guidelines indicate that <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> and <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a> may be considered (class II) in asymptomatic patients with a diagnosis of SQTS and a family history of SCD [<a href="#rid67">67</a>].</p><p>The available data, both experimental and clinical, suggest that all agents with Class III (QT prolonging) actions should be effective in all SQTS types with the exception of SQT1. This hypothesis remains to be more fully tested in clinical experience. </p><p>In the case of SQT3-6, representing an overlap between SQTS and BrS, the combination of <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> and <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a> has been shown to be effective, particularly in patients presenting with a VT/VF storm [<a href="#rid77">77</a>].</p><p>Atrial fibrillation (AF) is another common clinical problem in SQTS. Some patient with SQTS exhibit only AF [<a href="#rid78">78</a>]. <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">Propafenone</a> as well as <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> have been shown to be therapeutically effective is a small case series [<a href="#rid14">14</a>]. (See <a class="local">'Clinical presentation'</a> above.)</p><p class="headingAnchor" id="H26504555"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Timely diagnosis and optimal treatment improve the prognosis of patients with SQTS, although an accurate long-term prognosis in these patients remains difficult to assess. In contrast to the long QT syndrome, there is a paucity of data regarding SQTS in terms of its clinical presentation, diagnosis, genotype-phenotype correlation, risk-stratification, and treatment. </p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 25 pediatric patients (84 percent male, median age 15 years) who were followed for an average of six years, 14 patients (56 percent) experienced symptoms during follow-up, including aborted SCD and syncope [<a href="#rid79">79</a>]. Patients with a higher clinical risk score  (<a class="graphic graphic_table graphicRef65743" href="/d/graphic/65743.html" rel="external">table 2</a>) were more likely to be symptomatic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 34 patients (from a larger 73 patient cohort) who had all the required data available to assess the performance of the proposed prognostic SQTS score  (<a class="graphic graphic_table graphicRef65743" href="/d/graphic/65743.html" rel="external">table 2</a>), 21 patients had a score of ≤3, corresponding to a relatively "good" prognosis, with the remaining 13 patients having a score of 4 or greater, indicating a "poor" prognosis [<a href="#rid52">52</a>]. Among the eight patients who experienced a cardiac event, five of whom had a SQTS score ≤3, there was no significant difference in risk based on SQTS score, with an incidence of cardiac events of 4.6 percent per year in the "good" prognosis group and 4.2 percent per year in the "poor" prognosis group.</p><p></p><p>Markedly shortened QTc values ≤300 ms have been shown to be associated with increased risk of SCD, especially during sleep or rest, in young individuals, in whom the median QTc was 285 ms [<a href="#rid79">79,80</a>].</p><p>There is a scarcity of information concerning the long-term effectiveness of pharmacologic therapy. As such, pharmacologic therapy remains, for most patients, an adjunct to ICD treatment. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p class="headingAnchor" id="H881529096"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116416.html" rel="external">"Society guideline links: Inherited arrhythmia syndromes"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a>.)</p><p class="headingAnchor" id="H1561601237"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– Short QT Syndrome (SQTS) is an inherited channelopathy associated with marked shortening of QT intervals and sudden cardiac death (SCD) in individuals with structurally normal hearts. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">In SQTS, typical electrocardiogram (ECG) features include a QT interval &lt;360 milliseconds (range 220 to 360 milliseconds), absence of the ST segment, tall and peaked T waves in the precordial leads, and poor rate adaptation of the QT interval. (See <a class="local">'Electrocardiographic findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic basis </strong>– SQTS is a genetically heterogeneous disease with pathogenic variants in eight different genes (three gain-of-function and five loss-of-function) that encode different cardiac ion channels, a carnitine transporter, and chloride-bicarbonate anion exchanger  (<a class="graphic graphic_table graphicRef72304" href="/d/graphic/72304.html" rel="external">table 1</a>). (See <a class="local">'Genetic basis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and diagnosis </strong>– Whereas many patients are asymptomatic, the majority present with one or more of the following: SCD, palpitations, syncope, and atrial fibrillation. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">The sole presence of a shorter-than-normal QT interval is not always diagnostic of SQTS and may represent a normal variant. Diagnostic criteria have been developed to facilitate the evaluation of individuals suspected to have SQTS with a scoring system based on ECG characteristics, clinical presentation, family history, and genetic findings  (<a class="graphic graphic_table graphicRef65743" href="/d/graphic/65743.html" rel="external">table 2</a>). (See <a class="local">'Diagnosis and diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variant-specific genetic evaluation </strong>– This is recommended<strong> </strong>for all family members and relatives suspected of SQTS following the identification of the SQTS-causative mutation in an index case. Family members who test positive for the familial mutation should be seen by a cardiologist with expertise in SQTS for further management. (See <a class="local">'Screening family members'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired causes </strong>– These include hyperkalemia, acidosis, hypercalcemia, hyperthermia, effect of drugs like digitalis, increased vagal tone, and deceleration-dependent shortening of QT interval. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>–<strong> </strong>This depends on whether the short QT interval occurs in isolation or is associated with other clinical history, family history, or genetic criteria  (<a class="graphic graphic_table graphicRef65743" href="/d/graphic/65743.html" rel="external">table 2</a>) that increase the probability of SQTS. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a short QT interval (330 to 360 milliseconds) who have none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS are classified as low probability for the diagnosis of SQTS. For these low-probability patients, we suggest no specific pharmacologic or device-based therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a markedly shortened QT interval (&lt;330 milliseconds) are classified as intermediate probability for the diagnosis of SQTS, despite having none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS. For these intermediate-probability patients, we suggest no specific pharmacologic or device-based therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We do refer to an electrophysiologist for comprehensive testing, including genetic screening, if this has not yet been completed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with SQTS are at a very high risk for SCD. As such, we recommend implantable cardioverter-defibrillator (ICD) implantation for both primary and secondary prevention of SCD (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Implantable cardioverter-defibrillator'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pharmacologic therapy in patients with SQTS is primarily used as an adjunct to ICD placement. However, it may also be the primary treatment modality in patients who refuse or have contraindications to ICD placement or very young patients in whom ICD implantation is problematic. </p><p></p><p class="bulletIndent2">For patients with SQTS who have refused or are not candidates for ICD therapy, or in those with recurrent ventricular arrhythmias resulting in frequent ICD therapy, antiarrhythmic treatment is required. </p><p></p><p class="bulletIndent2">In the case of SQT1, we recommend <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> rather than a class IC or class III  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 4</a>) antiarrhythmic drug (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). This recommendation is based on the positive electrophysiologic effects of quinidine (eg, QT prolongation to the normal range) in patients with SQTS studied thus far. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H368878326"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. Jonathan M. Cordeiro for his contributions as an author to prior versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Algra A, Tijssen JG, Roelandt JR, et al. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J 1993; 70:43.</a></li><li><a class="nounderline abstract_t">Fei L, Camm AJ. Shortening of the QT interval immediately preceding the onset of idiopathic spontaneous ventricular tachycardia. Am Heart J 1995; 130:915.</a></li><li><a class="nounderline abstract_t">Kontny F, Dale J. Self-terminating idiopathic ventricular fibrillation presenting as syncope: a 40-year follow-up report. J Intern Med 1990; 227:211.</a></li><li><a class="nounderline abstract_t">Campbell TJ. Characteristics of cardiac action potentials in marsupials. J Comp Physiol B 1989; 158:759.</a></li><li><a class="nounderline abstract_t">Rezakhani A, Webster JD, Atwell RB. The electrocardiogram of the eastern grey kangaroo (Macropus giganteus). Aust Vet J 1986; 63:310.</a></li><li><a class="nounderline abstract_t">Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000; 94:99.</a></li><li><a class="nounderline abstract_t">Bjerregaard P. Diagnosis and management of short QT syndrome. Heart Rhythm 2018; 15:1261.</a></li><li><a class="nounderline abstract_t">Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: a familial cause of sudden death. Circulation 2003; 108:965.</a></li><li><a class="nounderline abstract_t">Cross B, Homoud M, Link M, et al. The short QT syndrome. J Interv Card Electrophysiol 2011; 31:25.</a></li><li><a class="nounderline abstract_t">Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 2011; 57:802.</a></li><li><a class="nounderline abstract_t">Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8:690.</a></li><li class="breakAll">Gussak I, Antzelevitch C, Goodman D, Bjerregaard P. Short QT interval: ECG phenomenon and clinical syndrome. In: Cardiac Repolarization. Bridging Basic and Clinical Sciences, Gussak I, Antzelevitch C (Eds), Humana Press, Totowa, NJ 2003. p.497.</li><li><a class="nounderline abstract_t">Gussak I, Bjerregaard P. Short QT syndrome--5 years of progress. J Electrocardiol 2005; 38:375.</a></li><li><a class="nounderline abstract_t">Bjerregaard P, Gussak I. Short QT syndrome. Ann Noninvasive Electrocardiol 2005; 10:436.</a></li><li><a class="nounderline abstract_t">Bjerregaard P, Gussak I. Short QT syndrome: mechanisms, diagnosis and treatment. Nat Clin Pract Cardiovasc Med 2005; 2:84.</a></li><li><a class="nounderline abstract_t">Anttonen O, Junttila MJ, Rissanen H, et al. Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. Circulation 2007; 116:714.</a></li><li><a class="nounderline abstract_t">Kobza R, Roos M, Niggli B, et al. Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. Heart Rhythm 2009; 6:652.</a></li><li><a class="nounderline abstract_t">Miyamoto A, Hayashi H, Yoshino T, et al. Clinical and electrocardiographic characteristics of patients with short QT interval in a large hospital-based population. Heart Rhythm 2012; 9:66.</a></li><li><a class="nounderline abstract_t">Mason JW, Ramseth DJ, Chanter DO, et al. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol 2007; 40:228.</a></li><li><a class="nounderline abstract_t">Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006; 27:2440.</a></li><li><a class="nounderline abstract_t">Hu D, Li Y, Zhang J, et al. The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome. JACC Clin Electrophysiol 2017; 3:727.</a></li><li><a class="nounderline abstract_t">Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109:30.</a></li><li><a class="nounderline abstract_t">Cordeiro JM, Brugada R, Wu YS, et al. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res 2005; 67:498.</a></li><li><a class="nounderline abstract_t">McPate MJ, Duncan RS, Milnes JT, et al. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C. Biochem Biophys Res Commun 2005; 334:441.</a></li><li><a class="nounderline abstract_t">Sun Y, Quan XQ, Fromme S, et al. A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol 2011; 50:433.</a></li><li><a class="nounderline abstract_t">Thorsen K, Dam VS, Kjaer-Sorensen K, et al. Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome. Nat Commun 2017; 8:1696.</a></li><li><a class="nounderline abstract_t">Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011; 32:1077.</a></li><li><a class="nounderline abstract_t">Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442.</a></li><li><a class="nounderline abstract_t">Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010; 7:1872.</a></li><li><a class="nounderline abstract_t">Roussel J, Labarthe F, Thireau J, et al. Carnitine deficiency induces a short QT syndrome. Heart Rhythm 2016; 13:165.</a></li><li><a class="nounderline abstract_t">Stanley CA. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004; 1033:42.</a></li><li><a class="nounderline abstract_t">Tein I. Role of carnitine and fatty acid oxidation and its defects in infantile epilepsy. J Child Neurol 2002; 17 Suppl 3:3S57.</a></li><li><a class="nounderline abstract_t">Ferro F, Ouillé A, Tran TA, et al. Long-chain acylcarnitines regulate the hERG channel. PLoS One 2012; 7:e41686.</a></li><li><a class="nounderline abstract_t">Campuzano O, Fernandez-Falgueras A, Lemus X, et al. Short QT Syndrome: A Comprehensive Genetic Interpretation and Clinical Translation of Rare Variants. J Clin Med 2019; 8.</a></li><li><a class="nounderline abstract_t">Walsh R, Adler A, Amin AS, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J 2022; 43:1500.</a></li><li><a class="nounderline abstract_t">Patel C, Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 2008; 5:585.</a></li><li><a class="nounderline abstract_t">Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004; 110:3661.</a></li><li><a class="nounderline abstract_t">Burashnikov A, Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol 2006; 29:290.</a></li><li><a class="nounderline abstract_t">McPate MJ, Zhang H, Adeniran I, et al. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study. J Physiol Pharmacol 2009; 60:23.</a></li><li><a class="nounderline abstract_t">Cordeiro JM, Greene L, Heilmann C, et al. Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol 2004; 286:H1471.</a></li><li><a class="nounderline abstract_t">Sah R, Ramirez RJ, Oudit GY, et al. Regulation of cardiac excitation-contraction coupling by action potential repolarization: role of the transient outward potassium current (I(to)). J Physiol 2003; 546:5.</a></li><li><a class="nounderline abstract_t">Schimpf R, Antzelevitch C, Haghi D, et al. Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm 2008; 5:241.</a></li><li><a class="nounderline abstract_t">Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109:2394.</a></li><li><a class="nounderline abstract_t">Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005; 96:800.</a></li><li><a class="nounderline abstract_t">Anttonen O, Väänänen H, Junttila J, et al. Electrocardiographic transmural dispersion of repolarization in patients with inherited short QT syndrome. Ann Noninvasive Electrocardiol 2008; 13:295.</a></li><li><a class="nounderline abstract_t">Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008; 41:567.</a></li><li><a class="nounderline abstract_t">Anttonen O, Junttila MJ, Maury P, et al. Differences in twelve-lead electrocardiogram between symptomatic and asymptomatic subjects with short QT interval. Heart Rhythm 2009; 6:267.</a></li><li><a class="nounderline abstract_t">Lu LX, Zhou W, Zhang X, et al. Short QT syndrome: a case report and review of literature. Resuscitation 2006; 71:115.</a></li><li><a class="nounderline abstract_t">Schimpf R, Bauersfeld U, Gaita F, Wolpert C. Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. Heart Rhythm 2005; 2:416.</a></li><li><a class="nounderline abstract_t">Fan X, Yang G, Kowitz J, et al. Preclinical short QT syndrome models: studying the phenotype and drug-screening. Europace 2022; 24:481.</a></li><li><a class="nounderline abstract_t">Odening KE, Bodi I, Franke G, et al. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility. Eur Heart J 2019; 40:842.</a></li><li><a class="nounderline abstract_t">Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol 2014; 63:1300.</a></li><li><a class="nounderline abstract_t">Ferrero-Miliani L, Holst AG, Pehrson S, et al. Strategy for clinical evaluation and screening of sudden cardiac death relatives. Fundam Clin Pharmacol 2010; 24:619.</a></li><li><a class="nounderline abstract_t">Jørgensen IN, Skakkebaek A, Andersen NH, et al. Short QTc interval in males with klinefelter syndrome-influence of CAG repeat length, body composition, and testosterone replacement therapy. Pacing Clin Electrophysiol 2015; 38:472.</a></li><li><a class="nounderline abstract_t">El-Battrawy I, Schlentrich K, Besler J, et al. Sex-differences in short QT syndrome: A systematic literature review and pooled analysis. Eur J Prev Cardiol 2020; 27:1335.</a></li><li><a class="nounderline abstract_t">Fish JM, Antzelevitch C. Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes. J Electrocardiol 2003; 36 Suppl:173.</a></li><li><a class="nounderline abstract_t">Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011; 58:587.</a></li><li><a class="nounderline abstract_t">Harrell DT, Ashihara T, Ishikawa T, et al. Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. Int J Cardiol 2015; 190:393.</a></li><li><a class="nounderline abstract_t">Frea S, Giustetto C, Capriolo M, et al. New echocardiographic insights in short QT syndrome: More than a channelopathy? Heart Rhythm 2015; 12:2096.</a></li><li><a class="nounderline abstract_t">Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol 2010; 3:401.</a></li><li><a class="nounderline abstract_t">Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 2005; 16:54.</a></li><li><a class="nounderline abstract_t">Tülümen E, Giustetto C, Wolpert C, et al. PQ segment depression in patients with short QT syndrome: a novel marker for diagnosing short QT syndrome? Heart Rhythm 2014; 11:1024.</a></li><li><a class="nounderline abstract_t">Watanabe H, Makiyama T, Koyama T, et al. High prevalence of early repolarization in short QT syndrome. Heart Rhythm 2010; 7:647.</a></li><li><a class="nounderline abstract_t">Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm 2010; 7:549.</a></li><li><a class="nounderline abstract_t">Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308.</a></li><li><a class="nounderline abstract_t">Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015; 17:1601.</a></li><li><a class="nounderline abstract_t">Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013; 10:1932.</a></li><li><a class="nounderline abstract_t">Zhang Y, Post WS, Dalal D, et al. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2011; 171:1727.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.</a></li><li><a class="nounderline abstract_t">Schimpf R, Wolpert C, Bianchi F, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol 2003; 14:1273.</a></li><li><a class="nounderline abstract_t">Morimoto Y, Watanabe A, Morita H, et al. Successful radiofrequency catheter ablation of a premature ventricular contraction triggering ventricular fibrillation in a patient with short QT syndrome. HeartRhythm Case Rep 2019; 5:262.</a></li><li><a class="nounderline abstract_t">Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004; 43:1494.</a></li><li><a class="nounderline abstract_t">Mazzanti A, Maragna R, Vacanti G, et al. Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. J Am Coll Cardiol 2017; 70:3010.</a></li><li><a class="nounderline abstract_t">McPate MJ, Duncan RS, Witchel HJ, Hancox JC. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 2006; 41:563.</a></li><li><a class="nounderline abstract_t">Mizobuchi M, Enjoji Y, Yamamoto R, et al. Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties. Pacing Clin Electrophysiol 2008; 31:1229.</a></li><li><a class="nounderline abstract_t">El Harchi A, Melgari D, Zhang YH, et al. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel. PLoS One 2012; 7:e52451.</a></li><li><a class="nounderline abstract_t">Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm 2016; 13:e295.</a></li><li><a class="nounderline abstract_t">Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 2005; 16:394.</a></li><li><a class="nounderline abstract_t">Villafañe J, Atallah J, Gollob MH, et al. Long-term follow-up of a pediatric cohort with short QT syndrome. J Am Coll Cardiol 2013; 61:1183.</a></li><li><a class="nounderline abstract_t">Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol 2014; 19:490.</a></li></ol></div><div id="topicVersionRevision">Topic 16697 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8037997" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : QT interval variables from 24 hour electrocardiography and the two year risk of sudden death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7572608" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Shortening of the QT interval immediately preceding the onset of idiopathic spontaneous ventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2313229" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Self-terminating idiopathic ventricular fibrillation presenting as syncope: a 40-year follow-up report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2715459" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Characteristics of cardiac action potentials in marsupials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3800805" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The electrocardiogram of the eastern grey kangaroo (Macropus giganteus).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11173780" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Idiopathic short QT interval: a new clinical syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29501667" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and management of short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925462" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Short QT Syndrome: a familial cause of sudden death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491125" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310316" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The short QT syndrome: proposed diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1422988" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sex differences in the evolution of the electrocardiographic QT interval with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1422988" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sex differences in the evolution of the electrocardiographic QT interval with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216616" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Short QT syndrome--5 years of progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16255754" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16265378" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Short QT syndrome: mechanisms, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679619" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19303371" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855519" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical and electrocardiographic characteristics of patients with short QT interval in a large hospital-based population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276451" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Electrocardiographic reference ranges derived from 79,743 ambulatory subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926178" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Short QT syndrome: clinical findings and diagnostic-therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759541" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14676148" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sudden death associated with short-QT syndrome linked to mutations in HERG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039272" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16011830" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21130771" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A novel mutation in the KCNH2 gene associated with short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29167417" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383000" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224476" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20817017" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26190315" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Carnitine deficiency induces a short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591002" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Carnitine deficiency disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12597056" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Role of carnitine and fatty acid oxidation and its defects in infantile epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22848566" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-chain acylcarnitines regulate the hERG channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31315195" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Short QT Syndrome: A Comprehensive Genetic Interpretation and Clinical Translation of Rare Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34557911" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362027" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569843" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606397" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439805" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14670817" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509475" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Regulation of cardiac excitation-contraction coupling by action potential repolarization: role of the transient outward potassium current (I(to)).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242547" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159330" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mutation in the KCNQ1 gene leading to the short QT-interval syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761194" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18713331" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Electrocardiographic transmural dispersion of repolarization in patients with inherited short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18790499" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : T(p-e)/QT ratio as an index of arrhythmogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187923" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Differences in twelve-lead electrocardiogram between symptomatic and asymptomatic subjects with short QT interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16942825" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Short QT syndrome: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851347" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34516623" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Preclinical short QT syndrome models: studying the phenotype and drug-screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30496390" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24291113" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Novel insight into the natural history of short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20698891" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Strategy for clinical evaluation and screening of sudden cardiac death relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25615644" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Short QTc interval in males with klinefelter syndrome-influence of CAG repeat length, body composition, and testosterone replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122038" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sex-differences in short QT syndrome: A systematic literature review and pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716629" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21798421" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term follow-up of patients with short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25974115" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26001507" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : New echocardiographic insights in short QT syndrome: More than a channelopathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20716721" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Short QT syndrome: from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673388" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24589867" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : PQ segment depression in patients with short QT syndrome: a novel marker for diagnosing short QT syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20206319" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : High prevalence of early repolarization in short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20153265" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : J wave syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787999" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26318695" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011539" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025428" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14678099" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193207" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Successful radiofrequency catheter ablation of a premature ventricular contraction triggering ventricular fibrillation in a patient with short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093889" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Short QT syndrome: pharmacological treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241489" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16842817" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18834480" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300672" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27423412" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15828882" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Short QT syndrome and atrial fibrillation caused by mutation in KCNH2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375927" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-term follow-up of a pediatric cohort with short QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24829126" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
